Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx
NCT00014118Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jun 2001
- Primary completion
- Mar 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and carboplatin in squamous cell carcinoma of the larynx (SCCL) and squamous cell carcinoma of the oropharynx (OPSCC) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Organ preservation rate, Feasibility and toxicity and 5 more. Started Jun 2001; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
squamous cell carcinoma of the larynx (SCCL)squamous cell carcinoma of the oropharynx (OPSCC)
Beyond the preview
Go deeper on NCT00014118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014118.